Other studies have shown that high expression of RFC2 is associated with poor survival in CRC, glioblastoma, and hepatocellular carcinoma and aids in predicting breast cancer progression and metastasis13,26,27. This evidence concerns the gene RFC2 and hepatocellular carcinoma.